Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
AN2 Therapeutics Inc (ANTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.96-6.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ANTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Report multiple data readouts within cash runway to 2029 | They plan multiple data reports before cash runs out in 2029. | Intact | No multiple data readouts reported before cash runs out in 2029 | Qualitative: Multiple data readouts reported (Sep 2026, Jun 2026) vs target before 2029 AN2 presented Epetraborole clinical data in Sep 2026 and reported NHP efficacy results in Jun 2026, confirming multiple data readouts. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Review the published break conditions above; missing evidence is not proof of success.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder: the company is loss-making and overall risk is high. Its thesis state is watch, with low confidence, despite management reporting progress on development plans and a recent earnings beat.
The snapshot gives no valuation measures or direct evidence of what the market assumes, so whether ANTX is cheap, fair, or expensive versus peers cannot be assessed. The available evidence does show a recent downward price reaction and performance below its industry cohort, but it does not establish the expectations already reflected in the shares.
Near term, results remain difficult to judge: ANTX had an earnings miss in May and a beat in August, while recent financial performance is rated neutral. Management says cash is sufficient to fund operations into 2029 and is preparing three programs for Phase 2 development, with multiple data readouts planned for 2026 and 2027. Execution risk remains high, and the next report is worth watching given the stated elevated miss risk.
Over the multi-year view, the thesis hinges on advancing the three programs and producing useful data within the stated cash runway. Near term, a guidance cut or further weakness in jobs data could add pressure, while continued strong results and guidance from healthcare peers could support the sector backdrop. These scenarios are uncertain, and overall confidence in the evidence is low.
ANTX has signs of clinical and partnership progress, but remains a high-risk, loss-making company with uneven recent results and limited valuation evidence. The 1-to-3-year view depends on execution and data readouts, not established earnings strength. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advance three programs into Phase 2 development |
| AN2 aims to advance three programs to Phase 2 this year. |
| Improving |
| Fails to advance 3 programs into Phase 2 by FY26 |
1 program advancing vs 3 target Clinical data supports Epetraborole advancement, but a failed drug poses a threat to the overall Phase 2 pipeline goals. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: ““AN2 will have three Phase 2 programs underway by the end of this year, all of which have the potential to address major unmet needs.” ““Looking ahead, we expect to advance three programs into Phase 2 development this year and report multiple data readouts within our cash runway into 2029.” Delivery assessment Nov 4, 2026 |
Progress in strategic partnership for Chagas disease study | A new partnership targets Chagas disease in primates. | Improving | No meaningful progress in Chagas disease partnership by FY26 | Qualitative progress: 28-day NHP efficacy data presented (Jun 2026) June 2026 strategic partnership event details 28-day NHP efficacy study for Chagas disease, confirming meaningful progress. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.93 → $-0.80 · observed estimates
$0.22B → $0.22B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.93 | $217,000,000 | 1 / 1 |
| 2026-07-25 | $-0.93 | $217,000,000 | 1 / 1 |
| 2026-07-26 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-07-27 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-07-28 | $-0.93 | $0 | 2 / 2 |
| 2026-07-29 | $-0.93 | $0 | 2 / 2 |
| 2026-07-30 | $-0.93 | $0 | 2 / 2 |
| 2026-07-31 | $-0.93 | $0 | 2 / 2 |
| 2026-08-01 | $-0.93 | $0 | 2 / 2 |
| 2026-08-02 | $-0.93 | $0 | 2 / 2 |
| 2026-08-03 | $-0.93 | $0 | 2 / 2 |
| 2026-08-04 | $-0.93 | $0 | 2 / 2 |
| 2026-08-05 | $-0.93 | $0 | 2 / 2 |
| 2026-08-06 | $-0.93 | $0 | 2 / 2 |
| 2026-08-07 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-08 | $-0.93 | $0 | 2 / 2 |
| 2026-08-09 | $-0.93 | $0 | 2 / 2 |
| 2026-08-10 | $-0.93 | $0 | 2 / 2 |
| 2026-08-11 | $-0.93 | $0 | 2 / 2 |
| 2026-08-12 | $-0.93 | $0 | 2 / 2 |
| 2026-08-13 | $-0.93 | $0 | 2 / 2 |
| 2026-08-14 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-15 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-16 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-17 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-18 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-19 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-20 | $-0.93 | $217,000,000 | 1 / 2 |
| 2026-08-21 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-22 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-23 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-24 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-25 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-26 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-27 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-28 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-29 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-30 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-08-31 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-01 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-02 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-03 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-04 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-05 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-06 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-07 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-08 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-09 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-10 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-11 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-12 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-13 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-14 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-15 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-16 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-17 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-18 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-19 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-20 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-21 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-22 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-23 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-24 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-25 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-26 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-27 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-28 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-29 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-09-30 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-01 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-02 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-03 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-04 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-05 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-06 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-07 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-08 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-09 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-10 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-11 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-12 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-13 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-14 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-15 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-16 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-17 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-18 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-19 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-20 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-21 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-22 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-23 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-24 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-25 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-26 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-27 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-28 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-29 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-30 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-10-31 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-11-01 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-11-02 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-11-03 | $-0.80 | $217,000,000 | 1 / 2 |
| 2026-11-04 | $-0.80 | $217,000,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The available assessments flag no unresolved thesis condition. The next results still need to support the ongoing thesis conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.